Pharmacology of beta 2 inhaler
Reading File
Finding Sources
Finding Sources
Searching PubMed
"beta2 agonist" AND asthma
Searching the Web
beta 2 agonist inhaler pharmacology mechanism of action salbutamol salmeterol
Reading File
Finding Sources
Reading File
Reading File
Reading File
Pharmacology of Beta-2 Agonist Inhalers
Mechanism of Action
Inhaled β2-agonists act on β2-adrenergic receptors, which are Gs protein-coupled receptors located on airway smooth muscle. Receptor stimulation activates adenylyl cyclase, raising intracellular cyclic AMP (cAMP), which activates protein kinase A. This lowers intracellular calcium and causes myosin light-chain kinase inhibition, producing relaxation of bronchial smooth muscle and bronchodilation. β2 receptors are also found on mast cells (inhibiting mediator release), cilia (increasing mucociliary clearance), and vascular smooth muscle (causing vasodilation) - Goodman & Gilman's Pharmacological Basis of Therapeutics, Ch. 44; Lippincott Illustrated Reviews: Pharmacology, Ch. 41.
Importantly, β2-agonists are bronchodilators only - they have no anti-inflammatory effect and should never be used as monotherapy in persistent asthma (Lippincott Pharmacology).
Classification
Short-Acting β2-Agonists (SABAs) - e.g., albuterol (salbutamol), levalbuterol, terbutaline
- Onset: 5-15 minutes (rapid, due to relatively hydrophilic structure that reaches the receptor via the aqueous phase)
- Duration: 3-6 hours
- Used as "reliever" therapy for acute bronchospasm and exercise-induced bronchoconstriction, on an as-needed basis
- Albuterol is a selective β2 agonist with pharmacology similar to terbutaline - Goodman & Gilman's, p. 1672-1680
Long-Acting β2-Agonists (LABAs) - e.g., salmeterol, formoterol, vilanterol
- Onset: slower for salmeterol (lipophilic, must partition through the membrane); formoterol has intermediate lipophilicity so it retains a fairly rapid onset similar to albuterol
- Duration: ~12 hours (up to 24h for once-daily agents like vilanterol)
- Used for maintenance, not acute rescue therapy - bind with greater affinity to the β2 receptor than albuterol
- LABAs must always be combined with an inhaled corticosteroid (ICS) in asthma - using a LABA alone increases the risk of asthma-related death (Tintinalli's Emergency Medicine, Table 69-5; Harrison's Principles of Internal Medicine, 22nd ed.)
Current GINA-based guidance (per Lippincott Pharmacology, Fig. 41.3) actually favors low-dose ICS-formoterol as the preferred reliever across most asthma severity steps, rather than a SABA alone, reflecting the shift toward reducing SABA-only reliance.
Adverse Effects (dose-related, from extrapulmonary β2 stimulation)
| Effect | Mechanism |
|---|---|
| Muscle tremor | Direct β2 stimulation of skeletal muscle receptors (most common side effect) |
| Tachycardia/palpitations | Reflex cardiac stimulation from peripheral vasodilation + direct atrial β2 stimulation (human heart has a notable proportion of β2 receptors) + β1 stimulation at higher doses |
| Hypokalemia | β2-mediated potassium entry into skeletal muscle (partly via insulin release); can be serious in hypoxic acute asthma, though clinically significant arrhythmias are rare |
| V/Q mismatch | Pulmonary vasodilation reverses hypoxic vasoconstriction, causing a small fall in PaO2 |
| Metabolic effects | Increased free fatty acids, insulin, glucose, lactate (mainly with high systemic doses) |
Side effects are uncommon with inhaled dosing but much more prominent with oral or IV administration - Goodman & Gilman's, Table 44-1.
Tolerance
Continuous use leads to receptor downregulation. Tolerance develops readily for non-airway effects (tremor, tachycardia, metabolic changes), and to a lesser but real degree for the bronchodilator effect itself with regular SABA/LABA use - Fishman's Pulmonary Diseases and Disorders; Goodman & Gilman's.
Pharmacokinetics (inhaled route)
Following inhalation, systemic absorption is largely local/topical to bronchial smooth muscle initially; a smaller fraction is swallowed and absorbed orally. Onset speed correlates with lipophilicity: hydrophilic albuterol acts fast in the aqueous receptor microenvironment, while lipophilic salmeterol has a delayed onset - reference from the Salbutamol in Asthma review (PMC9696300) and teachmepharmacy.info pharmacology summary, consistent with the textbook mechanism described above.
Recent Evidence (2024-2025 systematic reviews)
- Dose-response relationship of ICS/LABA combination inhalers in asthma maintenance therapy (PMID: 40912294)
- Efficacy of inhaled SABAs for acute wheeze in preschool children (PMID: 40122609)
- IV SABA as adjunct to standard therapy in severe pediatric asthma exacerbations (PMID: 40562456)
These don't contradict the core pharmacology above but refine dosing and adjunct-use nuances - worth reviewing if you're managing a specific clinical scenario.
Let me know if you want this broken down by a specific drug (e.g., albuterol vs. formoterol pharmacokinetics), a comparison table for exam prep, or clinical dosing/counseling points for inhaler technique.
This is a shared conversation. Sign in to Orris to start your own chat.